ClinicalTrials.gg
Status unknownNCT05287165Updated Mar 18, 2022

Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms

An Early Phase 1 interventional study of IM96 CAR-T cells in Advanced Solid Tumors, Digestive System Neoplasms and Pancreatic Cancer Resectable, sponsored by Beijing Immunochina Medical Science & Technology Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-03-18.

Sponsored by Beijing Immunochina Medical Science & Technology Co., Ltd. (part of Imunopharm Technology Co., Ltd.) · Early Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 75 studies in Digestive System Neoplasms with a site in China — 35 open to participants now, 40 under way, 4 of them phase 3. Digestive System Neoplasms · China.

Planned enrollment
58th of 64
19 · median 60
Started
2022
with 6 others
Phase 1
18 of 75
13 open now
Registered
37th of 75
by date

Among the 75 studies in Digestive System Neoplasms with a site in China, this one is the 58th largest by planned enrollment of the 64 interventional ones that give a count, is one of 7 that started in 2022, is one of 18 in phase 1, and was the 37th registered.

Digestive System Neoplasms

195 studies on the registry are indexed under Digestive System Neoplasms; 57 are open to participants now.

Browse Digestive System Neoplasms studies →

Open to participants now

35 of the 75 studies in Digestive System Neoplasms with a site in China are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 52 Digestive System Neoplasms studies recruiting now, 27 (52%) set no upper age limit and 17 (33%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Digestive System Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a open-label, single center to determine the efficacy and safety of IM96 CAR-T cells in Patients With Advanced Digestive System Neoplasms

03

Conditions studied

  • Advanced Solid Tumors
  • Digestive System Neoplasms
  • Pancreatic Cancer Resectable
  • Colorectal (Colon or Rectal) Cancer

Keywords

  • Digestive System Neoplasms
  • Pancreatic Cancer Resectable
  • Colorectal (Colon or Rectal) Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to 75 years, either sex;
  • Patients with diagnosed advanced gastrointestinal cancer:Patients with colorectal cancer who have failed or cannot tolerate or above standard treatment;Patients with unresectable locally advanced or metastatic pancreatic cancer who have failed or cannot tolerate first-line or above standard treatment; Patients with unresectable locally advanced or metastatic other gastrointestinal cancer (gastric cancer, esophageal cancer, small intestinal cancer, etc.) who have failed or cannot tolerate standard treatment, or have no standard treatment regimen;
  • At least one meeting 1.1 criteria;
  • Tumor tissue samples were positive for GUCY2C IHC staining;
  • Estimated >3 months;
  • (ECOG) performance status of 0 or 1;
  • Women of childbearing age who had a negative blood pregnancy test before the start of the trial and agreed to take effective measures during the trial period until the last follow-up; male subjects with fertility partners agreed to take effective contraceptive measures during the trial period until the last follow-up;
  • Adequate organ function;
  • Volunteer to participate in this trial and sign on the .

Exclusion criteria

Exclusion Criteria:

  • Patients have ;
  • Patients with a history of organ transplantation or awaiting organ transplantation;
  • The side effects caused by the previous treatment of the subjects did not return to ≤1; other tolerable events determined by investigator;
  • There is a large amount of serous effusion that cannot be controlled by treatment (such as pleural effusion, peritoneal effusion and pericardial effusion);
  • History of disease (eg Crohn's disease, rheumatoid arthritis, systemic lupus) within the last 2 years;
  • Presence of acute or chronic (GVHD);
  • Use prohibited drugs or treatments within a specified period of time before cell collection;
  • History or presence of CNS disorder, such as epilepsy, epileptic seizures, cerebrovascular disease (ischemia / hemorrhage / cerebral infarction), brain edema, reversible posterior white matter encephalopathy, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, cerebral organic syndrome or mental disease;
  • Chronic or active infections requiring systemic treatment, and a history of symptomatic viral infection that has not been completely cured;
  • received within 6 weeks before the start of screening;
  • Cardiac dysfunction includes: long syndrome or QTc interval > 480 MS; Complete left bundle branch block, grade II / III atrioventricular block; Serious and uncontrolled arrhythmias requiring drug treatment; A history of chronic congestive heart failure with ≥ 3, and the cardiac was less than 50% within 6 months before screening; Cardiac valvular disease with CTC AE ≥ 3; Myocardial infarction, cardiac angioplasty or stenting, unstable angina pectoris, history of severe pericardial disease or other heart diseases within 6 months before screening;
  • Patients requiring anticoagulant therapy;
  • Patients requiring continuous anti- therapy;
  • History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months of enrollment;
  • A history of other than non melanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast), unless it has been disease-free for at least 3 years;
  • Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring intravenous (IV) antimicrobials for management. Simple urinary tract infection (UTI) and bacterial pharyngitis are permitted if the investigator evaluates that it can be controlled by treatment, they can be included in the group;
  • Patients with gastrointestinal obstruction;
  • Patients at high risk of hemorrhage or perforation;
  • Patients were enrolled in another clinical study at the same time, unless it was an observational (non intervention) clinical study;
  • In the investigator's judgment, the subject is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
19 participants (estimated)

Study arms

  • Experimental
    IM96 CAR-T cells

    Drug: IM96 CAR-T cells

Interventions

  • treatment with anti-GUCY2C chimeric antigen receptor T-cell infusion

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment Related adverse events (AEs)

    Incidence of treatment related AE.

    Time frame: Up to 28 days after CAR-T cell infusion

Secondary outcomes

  1. Objective response rate (ORR)

    ORR, defined as the proportion of participants with a complete response or partial response, as determined by the investigator according to RECIST v1.1

    Time frame: Up to 24 weeks after CAR-T cell infusion

  2. Progression-free survival (PFS)

    PFS, defined as the time from CAR-T cell infusion to the first occurrence of disease progression or death from any cause (whichever occurs first) , as determined by the investigator according to RECIST v1.1

    Time frame: Up to 24 weeks after CAR-T cell infusion

  3. Duration of Response (DOR)

    DOR, defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first) in Stage 1, as determined by the investigator according to RECIST v1.1

    Time frame: Up to 24 weeks after CAR-T cell infusion

  4. Overall survival (OS)

    OS , defined as the time from CAR-T cell infusion to death from any cause

    Time frame: Up to 24 weeks after CAR-T cell infusion

  5. Persistence of CAR-T cells (cell counts and cell percentage in peripheral blood)

    The persistence over time of CAR T cells in the peripheral blood as determined by flow cytometry and qPCR.

    Time frame: Up to 24 weeks after CAR-T cell infusion

07

Study locations

1 of 1 sites recruiting
  • Beijing Cancer Hospital
    Beijing, Beijing 100142, China
    Recruiting
    • Lin Shen · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2022 (actual). Primary completion is estimated for Apr 2024, 25 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2022
First posted
Mar 18, 2022
StartActual
Mar 10, 2022
Primary completionEst.
Apr 30, 2024
CompletionEst.
Jun 30, 2024
Last update
Mar 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05287165
Responsible party
Sponsor
First posted
Mar 18, 2022
Start date
Mar 10, 2022
Primary completion
Apr 30, 2024 (estimated)
Completion
Jun 30, 2024 (estimated)
Last update
Mar 18, 2022

Study contacts

Fei Wu, MD
Contact
wufei@immunochina.com
+8615801390058
Lin Shen, Ph.D
principal investigator · Peking University Cancer Hospital & Institute

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IM96

Start the discussion